Randy McCollough, MD
Interventional Cardiology · Harker Heights, TXNPI 1972594281
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Abiomed at 52.9% of the total. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.
Across 32 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$320
- Siemens Medical Solutions USA, Inc.$80
- Medtronic$76
- Boston Scientific$34
- Cvrx, Inc.$33
- Abbott$23
- plus $39 from 2 others
What the payments were for
- Food & beverage$605100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 20 | $320 |
| Siemens Medical Solutions USA, Inc. | 2 | $80 |
| Medtronic | 3 | $76 |
| Boston Scientific | 2 | $34 |
| Cvrx, Inc. | 2 | $33 |
| Abbott | 1 | $23 |
| Itamar Medical Inc | 1 | $20 |
| Cordis US CORP. | 1 | $19 |
How this compares
$605 in reported general payments places this provider in the 0th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 207 | $221,758 |
| XareltoRivaroxaban | 104 | $118,099 |
| Repatha SureclickEvolocumab | 44 | $63,031 |
| EntrestoSacubitril/Valsartan | 18 | $24,176 |
| BrilintaTicagrelor | 18 | $23,050 |
| Atorvastatin Calcium | 323 | $3,797 |
| Metoprolol Succinate | 236 | $3,428 |
| ClopidogrelClopidogrel Bisulfate | 169 | $2,176 |
| Carvedilol | 181 | $1,986 |
| Prasugrel Hcl | 24 | $1,891 |
| Rosuvastatin Calcium | 84 | $1,657 |
| Flecainide Acetate | 43 | $1,556 |
| Lisinopril | 151 | $1,390 |
| Nebivolol Hcl | 15 | $1,356 |
| Amlodipine Besylate | 214 | $1,349 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Harker Heights
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
- Peter MonteleoneKyle$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.